7.5M
patients present with chest pain symptomatic of a possible heart attack (acute coronary syndrome) in the US each year.1 That’s one new patient every 4 seconds.
16%
of all deaths worldwide are due to ACS. That makes it the No. 1 cause of mortality.2
$188B
was the aggregate cost of treating ACS in 2008. By 2035 that cost is expected to double.3
IMT-358: An investigational drug under development by IMMEDIATE Therapeutics to be administered the first hours of a developing heart attack (i.e., ACS) to provide metabolic protection to the heart muscle, potentially minimizing cardiac damage and reducing cardiac instability that can lead to cardiac arrest. The efficacy of IMT-358 is under confirmation in a planned pivotal phase 3 trial.